Ally Bridge Group — 2018 Investments
1 investments dated 2018 · listed companies and verified rows first · show all
Epicrispr Biotechnologiesepicrispr.comin𝕏May 2018
Epic CRISPR develops GEMS (Gene Expression Modulation System), a modular epigenetic editing platform that combines DNA-binding proteins, guide RNAs, and modulator proteins to create genetic medicines.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesSouth San Francisco, US
Lei Stanley Qi(Scientific Founder)inAmber Salzman(Executive Officer, Director)inHaorui Zhang(Executive Officer, Director)
BoardAndrew Lam(Director)Anran Li(Director)Jennifer King(Director)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.